Lymphocyte-activation gene 3 (LAG-3) inhibitors represent the third class of immune checkpoint inhibitors (ICIs) and have been approved by the FDA for the treatment of melanoma in combination with nivolumab since 2022. The gene discussed is LAG3; the disease is melanoma.